---
id: asco-bladder-cancer-2024
title: "ASCO 2024 Guideline: Treatment of Muscle-Invasive and Metastatic Bladder Cancer"
short_title: "ASCO Bladder Cancer 2024"

organization: American Society of Clinical Oncology
collaborators: null
country: US
url: https://www.asco.org/guidelines
doi: null
pmid: null
open_access: true

specialty: oncology
guideline_type: clinical-practice
evidence_system: ASCO
conditions:
  - bladder cancer
  - urothelial carcinoma
  - muscle-invasive bladder cancer
tags:
  - cystectomy
  - neoadjuvant chemotherapy
  - immunotherapy
  - enfortumab vedotin
  - pembrolizumab

publication_date: 2024-07-01
previous_version_date: 2022-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 ASCO guideline update on the management of muscle-invasive and metastatic urothelial carcinoma of the bladder.

## Key Recommendations

### Muscle-Invasive Bladder Cancer (MIBC)

#### Neoadjuvant Chemotherapy
- **Cisplatin-Based Regimen (MVAC, ddMVAC, or GC)**: Recommended for cisplatin-eligible patients before radical cystectomy. Improves OS.

#### Surgery
- **Radical Cystectomy with Pelvic Lymph Node Dissection**: Standard of care for localized MIBC.
- Bladder-sparing trimodality therapy (TURBT + chemoradiation) is an option for select patients.

#### Adjuvant Therapy
- **Nivolumab**: For patients with residual high-risk disease (≥ypT2 or ypN+) after neoadjuvant chemo + cystectomy.

### Metastatic Bladder Cancer

#### First-Line (Cisplatin-Eligible)
- **Enfortumab Vedotin (EV) + Pembrolizumab**: Preferred first-line combination (EV-302 trial). Superior OS vs. chemo.
- **Gemcitabine + Cisplatin with Avelumab Maintenance**: Alternative. Switch maintenance to avelumab if no progression after 4-6 cycles chemo.

#### First-Line (Cisplatin-Ineligible)
- **EV + Pembrolizumab**: Also preferred.
- **Carboplatin + Gemcitabine → Avelumab Maintenance**: Alternative.
- **Pembrolizumab or Atezolizumab Monotherapy**: For PD-L1+ patients or those unsuitable for chemo.

#### Second-Line and Beyond
- **Enfortumab Vedotin**: If not used first-line.
- **Erdafitinib**: For FGFR2/3 alterations.
- **Sacituzumab Govitecan**: Antibody-drug conjugate.
- Immunotherapy if not used earlier.

### Biomarker Testing
- PD-L1, FGFR alterations (for erdafitinib eligibility), HER2.
